A study with ketoconazole and octreotide combination therapy for treatment of Cushing’s disease.
- Registry ID
- EUCTR2011-003264-77
- Source registry
- EUCTR
- Status
- Ongoing
- Phase
- PHASE2
- Sponsor
- Erasmus MC
- Start date
- 2011-09-05
- Last update
- 2026-08-16
Conditions
- Cushing's disease (which is caused by an ACTH producing pituitary adenoma)
Summary
The primary endopoint is to determine whether ketoconazole/octreotide combination therapy, followed by octreotide monotherapy, is an effective treatment for Cushing's disease.
Locations
View on source registry